Clinical TrialMay 6, 2026, 08:35 AM
Ernexa ERNA-101 Preclinical Data: Complete Tumor Clearance in Ovarian Cancer
AI Summary
Ernexa Therapeutics announced new preclinical data for its lead cell therapy candidate, ERNA-101, demonstrating complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models when combined with PD-1 blockade. These results significantly exceeded outcomes observed with either therapy alone, indicating potential curative activity and ERNA-101's ability to remodel the tumor microenvironment. The company plans to advance ERNA-101 towards a first-in-human clinical trial for advanced ovarian cancer, with potential to broaden indications to other solid tumors.
Key Highlights
- ERNA-101 combined with anti-PD-1 therapy achieved complete tumor clearance and 100% long-term survival in ovarian cancer models.
- The combination therapy significantly outperformed either therapy alone, suggesting potential curative activity.
- ERNA-101 remodeled the tumor microenvironment from immunosuppressive to immune-activated.
- Treatment enhanced immune cell activity, survival, and persistence of cancer-fighting T cells.
- Increased infiltration of CD4⁺ and CD8⁺ T cells into tumors was observed.
- Macrophage reprogramming shifted immune cells towards a cancer-fighting state.
- Reduced tumor burden and decreased ascites fluid accumulation were noted.
Price Impact
More from ERNA